Bookmark

Add to MyYahoo RSS

Lantus, Insulin Glargine News

News on Lantus, Insulin Glargine (generic) continually updated from thousands of sources around the net.

Friday Aug 22 | Drugs.com

FDA Grants Tentative Approval for Lilly and Boehringer...

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration today granted tentative approval for Basaglara , which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.

Comment?

Related Topix: Eli Lilly, Food and Drug Administration, Ridgefield, CT, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin

Thu Aug 21, 2014

Hispanic Business

Zealand Pharma A/S - Interim report for H1 2014

Ex-US market roll-out of Lyxumia by Sanofi continues with several new launches in Q2 2014 and additional launches expected over the rest of the year -- Broad-based pipeline progress - internal and external -- LixiLan Phase III trials advanced by Sanofi with completion expected in H2 2015 -- Plans on track for US filing of Lyxumia in Summer 2015 and ... (more)

Comment?

Related Topix: Medicine, Diabetes, Health

Mon Aug 18, 2014

Sys-Con Media

FDA Grants Tentative Approval for Lilly and Boehringer...

Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company and Boehringer Ingelheim's basal insulin, which is intended to provide long-lasting blood sugar control in between meals and during the night.1 Basaglar has the same amino acid sequence as the currently marketed insulin glargine product and was ... (more)

Comment?

Related Topix: Food and Drug Administration, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin, Biotech, Eli Lilly, Healthcare Industry

Seeking Alpha

Eli Lilly: Strong Future Prospects Will Restore The Company's Financials

Patent expiries of Cymbalta and Evista have strangled Eli Lilly's quarterly performance this time.

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, Diabetes, Health, Pancreatic Cancer

Fri Aug 15, 2014

GuruFocus.com

Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza

MannKind has seen volatile price swings upon the partnership announcement for Afrezza with Sanofi .

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Sales, Marketing

Tue Aug 12, 2014

Seeking Alpha

MannKind: Looking Beyond The Short-Term Disappointment

MannKind Corporation and France-based Sanofi announced early yesterday morning that they have entered into a worldwide exclusive licensing agreement for the development and commercialization of AfrezzaA , MannKind's recently approved rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.

Comment?

Related Topix: Biotech, MannKind, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Marketing

Mon Aug 11, 2014

Reuters

eb UPDATE 1-Sanofi bets on inhaled insulin with up to $925 mln MannKind deal

French drugmaker Sanofi is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp worth up to $925 million.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health

Fri Aug 08, 2014

Contract Pharma Breaking News

Financial Report: Sanofi

Sanofi 2Q Revenues: 8.1 billion 2Q Earnings: 1.5 billion YTD Revenues: 15.9 billion YTD Earnings: 3.1 billion Comments: Pharmaceutical sales were up 7% to 6.8 billion.

Comment?

Related Topix: Medicine, Health, Diabetes

Thu Aug 07, 2014

Seeking Alpha

Sanofi: Confronting Lantus Patent Expiry With More Efficient Successor Toujeo

Sanofi received the US FDA's acceptance for reviewing its New Drug Application for investigational basal insulin, Toujeo.

Comment?

Related Topix: Biotech, SanofiSynthlabo, Medicine, Insulin (generic), Humulin, Novolin, Healthcare Law, Food and Drug Administration, Law, Eli Lilly, Healthcare Industry

Wed Aug 06, 2014

Mydigitalfc.com

Lupin inks pact with South Korean firm to launch diabetes drug

Drug major Lupin has inked a marketing pact with South Korea's LG Life Sciences to launch its anti-diabetes drug in India.

Comment?

Related Topix: Medicine, Diabetes, Health, Marketing, World News, India, Insulin (generic), Humulin, Novolin

Thu Jul 31, 2014

The Washington Post

Sanofi Raises Profit Forecast as Earnings Gain on Pricing

Sanofi raised its profit forecast for the year after reporting higher second-quarter earnings as it benefits from increased prices in the U.S. for its top- selling product, the diabetes medicine Lantus.

Comment?

Related Topix: Medicine, Diabetes, Health, Business News

Wed Jul 30, 2014

JD Supra

Court Report -- Part II - July 2014 #2

Acorda Therapeutics Inc. v. Actavis Laboratories FL Inc. 1:14-cv-00882; filed July 7, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos.

Comment?

Related Topix: Biotech, Medicine, Acorda Therapeutics, Healthcare Industry, Eli Lilly, Insulin (generic), Humulin, Novolin, Diabetes, Health, Dr Reddys Laboratories

•••
•••
•••
•••
•••
•••
•••